Common Stock, par value $0.000041666
- Symbol
- IOVA
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 8.01, 9.01 · 8-K
Iovance Biotherapeutics, Inc.
IOVANASDAQEQUITYCurrent
Other Events
Item 8.01 Other Events. On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press release updating its full year 2026 revenue guidance. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.
Press release in this filing
Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million →Company context
Iovance Biotherapeutics, Inc. is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at nearly 100 authorized treatment centers (ATCs). The Iovance TIL platform spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. Headquartered in Pennsylvania with offices and laboratories in California and Florida, Iovance serves patients at ATCs and clinical sites across almost the entire U.S. and in many countries around the world. For more information, please visit www.iovance.com.
Current securities
Registered securities in this filing
IOVANCE BIOTHERAPEUTICS, INC. · 8-K · Filed 2026-09-29
Disclosure sections
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On September 29, 2026, Iovance Biotherapeutics, Inc. issued a press
release updating its full year 2026 revenue guidance. A copy of the press release is attached as Exhibit 99.1 and is incorporated herein
by reference.
Filed exhibits (1)
Exhibit 99.1 Iovance Biotherapeutics Raises Full Year 2026 Revenue Guidance to $410 to $420 Million New Guidance Represents an Increase of $55 Million at the Midpoint from the Prior Range of $350 to $370 Million Strong U.S. Demand for Amtagvi and Proleukin Drives Increased Outlook PHILADELPHIA, Pennsylvania, September 29, 2026 -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today raised its full year 2026 total revenue guidance range to $410 to $420 million, driven by strong U.S. demand for Amtagvi® (lifileucel) and Proleukin. The midpoint represents an increase of $55 million, or ~15%, over the previous guidance range of $350 to $370 million and implies nearly 60% annual growth in total revenue. “Our record second quarter and sustained demand for Amtagvi and Proleukin led us to raise our full year 2026 total revenue guidance by $55 million at the midpoint,” said Frederick Vogt, Ph. D., J.D., Interim President and Chief Executive Officer. “Increasing patient demand and our current manufacturing schedule p…
Open exhibit ↗